Close
(0) items
You have no items in your shopping cart.
All Categories
    Filters
    Preferences
    Search

    Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis

    €56.25
    This book provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. The book covers state-of-the-art approaches to the design and analysis of cancer clinical trials, such as adaptive designs, biomarker-based trials, and dynamic treatment regimes.
    ISBN: 9780367261177
    AuthorGeorge, Stephen L. (Duke University Scho
    SubAuthor1Wang, Xiaofei (Duke University School of
    SubAuthor2Pang, Herbert (University of Hong Kong S
    Pub Date22/03/2019
    BindingPaperback
    Pages454
    AvailabilityCurrently out of stock. If available, delivery is usually 5-10 working days.
    Availability: Out of Stock

    Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. Well-known statisticians from academic institutions, regulatory and government agencies (such as the U.S. FDA and National Cancer Institute), and the pharmaceutical industry share their extensive experiences in cancer clinical trials and present examples taken from actual trials.





    The book covers topics that are often perplexing and sometimes controversial in cancer clinical trials. Most of the issues addressed are also important for clinical trials in other settings. After discussing general topics, the book focuses on aspects of early and late phase clinical trials. It also explores personalized medicine, including biomarker-based clinical trials, adaptive clinical trial designs, and dynamic treatment regimes.

    Write your own review
    • Only registered users can write reviews
    *
    *
    • Bad
    • Excellent
    *
    *
    *

    Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis provides statisticians with an understanding of the critical challenges currently encountered in oncology trials. Well-known statisticians from academic institutions, regulatory and government agencies (such as the U.S. FDA and National Cancer Institute), and the pharmaceutical industry share their extensive experiences in cancer clinical trials and present examples taken from actual trials.





    The book covers topics that are often perplexing and sometimes controversial in cancer clinical trials. Most of the issues addressed are also important for clinical trials in other settings. After discussing general topics, the book focuses on aspects of early and late phase clinical trials. It also explores personalized medicine, including biomarker-based clinical trials, adaptive clinical trial designs, and dynamic treatment regimes.